Sara Casciato

Sara Casciato

Auto-generated profile, based on publicly available information

Sara Casciato

Department of Neurology and Psychiatry, Sapienza University of Rome, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Neuropharmacology
Verified
Journal Article
Closed access
RNRichard Teke Ngomba
Richard Teke Ngomba
FBFrancesca Biagioni
Francesca Biagioni
SCS. Casciato
S. Casciato
EBE. Willems-Van Bree
E. Willems-Van Bree
GBGiuseppe Battaglia
Giuseppe Battaglia
ELE.L.J.M. van Luijtelaar
E.L.J.M. van Luijtelaar

11 January 2010 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
JFJ. Fattouch
J. Fattouch
CBCarlo Di Bonaventura
Carlo Di Bonaventura
SCS. Casciato
S. Casciato
FBF. Bonini
F. Bonini
SPS. Petrucci
S. Petrucci
AGA. T. Giallonardo
A. T. Giallonardo

7 February 2012 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MFMartina Fanella
Martina Fanella
JFJinane Fattouch
Jinane Fattouch
SCSara Casciato
Sara Casciato
LLLeonardo Lapenta
Leonardo Lapenta
AMAlessandra Morano
Alessandra Morano
CBCarlo Di Bonaventura
Carlo Di Bonaventura

1 September 2012 in Epilepsy & Behavior
Verified
Journal Article
Closed access
JFJ. Fattouch
J. Fattouch
CBC. Di Bonaventura
C. Di Bonaventura
LLL. Lapenta
L. Lapenta
SCS. Casciato
S. Casciato
MFM. Fanella
M. Fanella
AGA.T. Giallonardo
A.T. Giallonardo

1 July 2018 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
AMAlessandra Morano
Alessandra Morano
JFJinane Fattouch
Jinane Fattouch
MAMariarita Albini
Mariarita Albini
SCSara Casciato
Sara Casciato
MFMartina Fanella
Martina Fanella
CBCarlo Di Bonaventura
Carlo Di Bonaventura

3 May 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
EIEmanuele Cerulli Irelli
Emanuele Cerulli Irelli
Enrico CocchiEnrico Cocchi
Enrico Cocchi
GRGeorgia Ramantani
Georgia Ramantani
RCRoberto H. Caraballo
Roberto H. Caraballo
LGLoretta Giuliano
Loretta Giuliano
OGon behalf of the EMA Study Group
on behalf of the EMA Study Group
Background and objectives: Eyelid myoclonia with absences (EMA) is a generalized epilepsy syndrome whose prognosis and clinical characteristics are still partially undefined. We investigated electroclinical endophenotypes and long-term seizure outcome in a large cohort of EMA patients. Methods: In this multicenter retrospective study, EMA patients with ≥5 years of follow-up were included. We investigated prognostic patterns and sustained terminal remission (STR), along with their prognostic factors. Moreover, a two-step cluster analysis was used to investigate the presence of distinct EMA endophenotypes. Results: We included 172 patients, with a median age at onset of 7 years (interquartile range (IQR) 5-10) and a median follow-up duration of 14 years (IQR 8.25-23.75). Sixty-six patients (38.4%) displayed a non-remission pattern, whereas remission and relapse patterns were encountered in 56 (32.6%) and 50 (29.1%) subjects. Early epilepsy onset, history of febrile seizures (FS) and eyelid myoclonia (EM) status epilepticus significantly predicted a non-remission pattern according to multinomial logistic regression analysis. STR was achieved by 68 (39.5%) patients with a mean latency of 14.05 years (SD ± 12.47). Early epilepsy onset, psychiatric comorbidities, and a history of FS and generalized tonic-clonic seizures (GTCS) were associated with a lower probability of achieving STR according to a Cox regression proportional hazards model. Antiseizure medication (ASM) withdrawal was attempted in 62/172 patients, and seizures relapsed in 74.2%. Cluster analysis revealed two distinct clusters with 86 patients each. Cluster 2, which we defined as “EMA-plus”, was characterized by an earlier age at epilepsy onset, higher rate of intellectual disability, EM status epilepticus, generalized paroxysmal fast activity, self-induced seizures, FS, and poor ASM response, whereas Cluster 1, the “EMA-only” cluster, was characterized by a higher rate of seizure remission and more favorable neuropsychiatric outcome. Discussion: Early epilepsy onset was the most relevant prognostic factor for poor treatment response. A long latency between epilepsy onset and ASM response was observed, suggesting the impact of age-related brain changes in EMA remission. Finally, our cluster analysis showed a clear-cut distinction of EMA patients into an EMA-plus insidious subphenotype and an EMA-only benign cluster that strongly differed in terms of remission rates and cognitive outcomes.